Navigation Links
KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
Date:9/3/2013

SUNNYVALE, Calif. (PRWEB) September 03, 2013

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that KBI Biopharma, Inc. (KBI), a leading development and contract manufacturing organization serving the biopharmaceutical industry, has purchased Freeslate’s Biologics Formulation System to help develop more robust formulations using less time and material. The Biologics Formulation System is based on Freeslate’s Core Module 3 (CM3) automation platform and provides a new, high throughput research approach to address challenges in biologics formulation.

“The KBI team is excited to begin using Freeslate’s Biologics Formulation System to support our biologics formulation screening during early-stage development, as well as formulation robustness studies and process optimization during later stage development”, said Joseph McMahon, President and CEO for KBI. “We selected Freeslate’s technology because the system was designed for biologics formulation, combining key capabilities that can be used across both early and late stage development projects allowing us to screen a broader range of conditions and reduce product consumption while accelerating our clients’ development timelines.”

“At Freeslate, we are dedicated to advancing biologics formulation with integrated, automated solutions that address the complex problems of drug development,” said John S. Senaldi, President and CEO of Freeslate. “We have built strong capabilities in this area and are pleased to partner with KBI to continue those advances and support the important research they are doing on behalf of their clients.”

Freeslate’s Biologics Formulation System supports the entire formulation develo
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
3. CeNeRx BioPharma Completes $4.85 Million Financing
4. PDL BioPharma Completes Regular Quarterly Dividend Payment
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
7. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
10. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
11. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 26, 2015 Research ... of the "Global Breast Cancer Monoclonal Antibodies ... Globally, Roche seems to dominate the ... inventory. Its block buster molecule, Herceptin has been ... It was found that breast cancer cells become ...
(Date:5/27/2015)... Fla. (PRWEB) May 27, 2015 Expanding ... dental cement manufacturer Avalon Biomed Inc. recently ... of Mokuda Dental Co. Ltd. , the largest ... inroad into the international market for Avalon Biomed, which ... Plus®, award-winning tricalcium silicate-based dental cements that have won ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... MB (PRWEB) May 27, 2015 ... data to combat disease, Cubresa Inc. today announced ... “Our MR Compatible in-bore PET Scanner uses silicon ... into single-purpose preclinical MRI machines from manufacturers like ... Cubresa, headquartered in Winnipeg, Canada. “This enables simultaneous ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2
... , SAN DIEGO , INDIANAPOLIS and WALTHAM, Mass. ... AMLN ), Eli Lilly and Company (NYSE: LLY ) and ... and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable ... Prescription Drug User Fee Act (PDUFA) action date of October 22, ...
... , May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... and Drug Administration (FDA), orphan-drug designation for AEZS-108, its ... cancer. AEZS-108 is currently in a Phase 2 trial ...
... Belgium and LUND, Sweden , May 6, 2010 , ... - TB-402 Demonstrates Superior Antithrombotic ... ThromboGenics ... from,their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant,that is ...
Cached Biology Technology:BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 3BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 4BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 5BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 6BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 7BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 8Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 2ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 3ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 4ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 5ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 6ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 7
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... life forms that have been around since the dinosaurs, ... because they can simultaneously produce other valuable products ... Engineers at Oregon State University concede that such ... not science fiction many of the needed advances ...
... tested a new technique to ensure fresh produce is free ... particles created when gases are excited by an energy source. ... research shows, some can hide from its effects in the ... and vegetables is promoted as part of a healthy lifestyle, ...
... National Heart, Lung, and Blood Institute, part of the ... to Albert Einstein College of Medicine ... study of hemoglobin toxicity that may complicate blood transfusions ... goals include making blood transfusions safer and more effective ...
Cached Biology News:Ancient diatoms could make biofuels, electronics and health food -- at the same time 2Assessing a new technique for ensuring fresh produce remains Salmonella-free 2Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin 2
... EZ-Spread Plating Beads Sterile plating in ... glass rods and potentially hazardous ethanol flaming, ... choices of ready-to-use sterile packaging: dispenser bottle for ... plating, Fastest and easiest way to ...
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
... IgY) , After we receive your antigen (see ... appropriate number of chickens and begin to collect ... (usually over a period of 3-5 days), we ... of four injections into the breast muscle. The ...
Biology Products: